Abstract
We evaluated density of the natural killer (NK) cell-associated CD56 antigen on circulating NK cells of 47 patients with advanced renal cell carcinoma. Patients received a combination of low-dose subcutaneous recombinant interleukin-2 (rIL-2) and recombinant interferon-alpha (rIFN-alpha) as home therapy. Antigen density of CD56 before therapy was 2.2-fold higher (P < 0.005) in patients who subsequently achieved a complete or partial remission when compared with patients who presented with progressive disease on therapy. After a 6-week treatment cycle, NK cells of treatment responders expressed significantly (2.1-fold; P < 0.005) more CD56 antigens than NK cells in nonresponding patients. These results suggested a potential role of both pre- and posttreatment NK antigen density levels as a biologic correlate to treatment response.
MeSH terms
-
Antigens, CD / metabolism*
-
Antigens, Differentiation, T-Lymphocyte / metabolism*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / metabolism
-
CD56 Antigen
-
Carcinoma, Renal Cell / immunology
-
Carcinoma, Renal Cell / therapy*
-
Cell Count
-
Flow Cytometry
-
Humans
-
Injections, Subcutaneous
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / therapeutic use*
-
Interleukin-2 / administration & dosage
-
Interleukin-2 / therapeutic use*
-
Kidney Neoplasms / immunology
-
Kidney Neoplasms / therapy*
-
Killer Cells, Natural / immunology*
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / therapeutic use
-
Treatment Outcome
Substances
-
Antigens, CD
-
Antigens, Differentiation, T-Lymphocyte
-
Biomarkers, Tumor
-
CD56 Antigen
-
Interferon-alpha
-
Interleukin-2
-
Recombinant Proteins